Melanoma Research Victoria

Source: OncLive, November 2018 Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses how to choose between available combination therapies in the treatment of patients with melanoma. There are 3 combinations of BRAF and MEK inhibitors that have […]

Read the full story

Source: Onclive, November 2018 Merrick I. Ross, MD: Decision making is always a difficult situation when patients have choices. Different oncologists may have biases as well. When the patient has a BRAF mutation, they certainly have multiple options. They could receive targeted therapy, and there’s no reason why they can’t receive immunotherapy. As a matter of fact, if […]

Read the full story

Source: Onclive, October 2018 Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of pembrolizumab (Keytruda) in the treatment of patients with relapsed melanoma. Based on the significant impact of overall survival (OS) that has been seen in clinical trials with pembrolizumab as […]

Read the full story

Source: Onclive, November 2018 Jeffrey S. Weber, MD, Ph.D.: This has been a very informative discussion. Before we end the discussion, I’d like to close with some thoughts from each of the panelists. Dr. Andtbacka? Robert Andtbacka, MD, CM: From the earlier stage, from the surgical perspective, I think that melanoma surgery has changed quite a bit. […]

Read the full story